The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2030-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

NCT04576377

Influenza, Human

ACTIVE_NOT_RECRUITING PHASE4

Immune Response Study of Influenza Vaccine

NCT01310374

Influenza Vaccine Allergy Cell Mediated Reaction

COMPLETED

Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults

NCT01730144

Normal Physiology

COMPLETED

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

NCT02387294

Human Influenza

COMPLETED PHASE3

Immunologic Response to Influenza Vaccination in Children and Adolescents

NCT03614975

Influenza, Human Immune Response

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Annual vaccination remains a key public health approach to reducing the impact of influenza virus infections. However, numerous trials and observational studies, including our own, have demonstrated that repeated an-nual influenza vaccination can result in attenuated vaccine effectiveness in some years in a phenomenon called "repeat vaccination effects". Gaining insight into the varying efficacy of influenza vaccines across different individuals and populations is crucial for optimizing the use of current vaccines and designing universal ones. However, understanding the changes in vaccine effectiveness and immunogenicity among those receiving repeated vaccinations is challenging, especially in populations where universal vaccination is recommended. Repeated vaccinees differ significantly from both new vaccinees and non-vaccinees, potentially leading to residual con-founding in infection and vaccination histories, making it hard to isolate the effects of the vaccine itself.

The investigators will conduct a randomized trial to explore the effects of repeated vaccination and their immunological foundations in a population with low vaccine coverage and no influenza vaccination recommendation. The study will involve live attenuated influenza vaccines (FluMist, nasal spray) in addition to parenteral influenza vaccines (Flublok, injected) to stimulate different components of the immune system. The trial will involve 600 adults in Hong Kong, divided into four groups. The four groups will receive annual vaccination with Flublok, FluMist, alternating between these two vaccines, or alternating between Flublok and placebo. This structure enables comparisons of humoral, mucosal and cellular vaccine responses after different combinations of vaccines.

The resulting longitudinal data on immune status and influenza-specific responses will allow the investigators to develop predictive models for vaccine and infection responses, including those involving repeat vaccinations. The planned immunological profiling, alongside advanced statistical analysis, will enhance understanding of repeated vaccination's effects on seasonal influenza and inform strategies to anticipate vaccine non-responsiveness and improve vaccination approaches. Stored specimens will also allow future testing of new hypotheses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Intervention Type BIOLOGICAL

0.5mL recombinant hemagglutinin influenza vaccine (Flublok, Sanofi)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Live attenuated influenza vaccine

0.2mL nasal spray live attenuated influenza vaccine (FluMist, AstraZeneca)

Intervention Type BIOLOGICAL

Placebo nasal spray

0.2mL saline placebo nasal spray

Intervention Type BIOLOGICAL

recombinant hemagglutinin influenza vaccine

0.5mL recombinant hemagglutinin influenza vaccine (Flublok, Sanofi)

Intervention Type BIOLOGICAL

Placebo injection

0.5mL saline placebo injection

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 22-50 years at enrolment.
2. A. Participated in the DRIVE I or DRIVE II studies (for DRIVE IIIa). OR B. Did not participate in the DRIVE I or DRIVE II study (for DRIVE IIIb) and has not received influenza vaccination in the prior two years.
3. Capable of providing informed consent.
4. Resident in Hong Kong in the coming 2 years.

Exclusion Criteria

1. Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition ), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry).
2. With diagnosed medical conditions related to their immune system.
3. Currently taking medication for any condition that impairs immune system.
4. Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:

* Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component;
* Moderate or severe acute illness with or without fever after any previous influenza vaccination; or
* A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination.
5. Individuals who report medical conditions not suitable to receive live attenuated vaccines, such as:

* having asthma;
* having close contact with severely immunosuppressed persons who require a protected environment; or
* having immunosuppressive treatment (e.g. high-dose steroid, anti-cancer drugs and radiotherapy).
6. Individuals who report medical conditions not suitable to receive intramuscular injection, such as

* Bleeding disorders
* Habitually taking anticoagulants (with the exception of antiplatelets such as aspirin).
7. Individuals who have any medical conditions not suitable to receive inactivated or live attenuated influenza vaccines as determined by a clinician.

Minimum Eligible Age

22 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes